New Clinical Guidance on the Use of JAK Inhibitors for Patients with Moderate-to-Severe Rheumatoid Arthritis: How Does Your Approach Compare with the Experts’?

Friday, September 23, 2022

12:00PM – 1:00PM ET

Please note this TeleECHO program is 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain and 9:00AM Pacific.

PROGRAM OVERVIEW

This TeleECHO series has been designed for US-based rheumatologists, nurses, and allied healthcare professionals involved in the management of patients with rheumatoid arthritis (RA), to better interpret data from clinical trials supporting the efficacy, safety, and tolerability of JAK inhibitors (JAKi) with different mechanisms of action in patients with moderate-to-severe RA. This series will help health professionals incorporate new evidence-based management recommendations on the use of JAKi for patients with moderate-to-severe RA into clinical practice, and it also supports patient-centered multidisciplinary team-based approaches to the management of those patients with moderate-to-severe RA.

FACULTY

Joerg Ermann, MD
Division of Rheumatology, Inflammation and Immunity
Brigham and Women’s Hospital
Boston, MA

Target Audience

This activity is intended for US-based rheumatologists, nurses, and allied healthcare professionals involved in the management of patients with RA.

Learning Objectives

Upon the completion of this program, attendees should be able to:

  • Interpret data from clinical trials supporting the efficacy, safety, and tolerability of JAKi with different mechanisms of action in patients with moderate-to-severe RA
  • Incorporate new evidence-based management recommendations on the use of JAKi for patients with moderate-to-severe RA into clinical practice
  • Support patient-centered multidisciplinary team-based approaches to the management of those with moderate-to-severe RA

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with rheumatoid arthritis.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

Med Learning Group makes every effort to develop CME activities that are science-based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/